The Waxing and Waning of Antithrombotic Therapy in Cardiovascular Disease - Where Is the Moon Now?

Prog Cardiovasc Dis. 2018 Jan-Feb;60(4-5):457-459. doi: 10.1016/j.pcad.2018.01.011. Epub 2018 Jan 31.

Authors

Mark B Effron¹, C Michael Gibson²

Affiliations

¹ Division of Consultative Cardiology, John Ochsner Heart and Vascular Institute, Ochsner Clinical School, University of Queensland (Australia) School of Medicine, New Orleans, LA 7012, United States. Electronic address: mark.effron@ochsner.org.
² PERFUSE Study Group, Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, United States.

PMID: 29366879
DOI: 10.1016/j.pcad.2018.01.011

No abstract available

Publication types

Editorial
Introductory Journal Article

MeSH terms

Acute Coronary Syndrome / therapy*
Anticoagulants / pharmacology*
Atrial Fibrillation / drug therapy*
Atrial Fibrillation / therapy
Coronary Thrombosis / therapy*
Fibrinolytic Agents / pharmacology*
Humans
Percutaneous Coronary Intervention / methods
Risk Assessment
Treatment Outcome

Substances

Anticoagulants
Fibrinolytic Agents